...
首页> 外文期刊>Journal of Pharmaceutical and Biomedical Analysis: An International Journal on All Drug-Related Topics in Pharmaceutical, Biomedical and Clinical Analysis >Level A in vitro-in vivo correlation: Application to establish a dissolution test for artemether and lumefantrine tablets
【24h】

Level A in vitro-in vivo correlation: Application to establish a dissolution test for artemether and lumefantrine tablets

机译:在体外体内相关性:用于建立伪醚和Lumefantrine片剂的溶出试验的应用

获取原文
获取原文并翻译 | 示例
           

摘要

Malaria is the most incident parasite infection worldwide. Artemisinin based combination therapy (ACT) has been proposed as a promising treatment for malaria, and artemether + lumefantrine (20 +120 mg) is the recommended association in endemic areas. Despite its widespread use, there is still scarce information about dissolution of artemether and lumefantrine, reflecting in the absence of a specific method in pharmacopoeias and international compendia. Because the of their low solubility, both artemether and lumefantrine are candidates for in vitro-in vivo correlation (IVIVC) studies. Previous equilibrium solubility studies have been carried out for both drugs using the shake-flask method and dissolution profiles. Experiments were conducted with a range of parameters such as medium composition, pH and surfactants. In vivo data obtained in a previous pharmacokinetic study was used to select the optimum conditions for dissolution test, based on IVIVC. For drug quantitation, a selective method by high performance liquid chromatography was optimized and validated. For this dosage form, the best dissolution conditions found for artemether were: paddles, 900 mL of dissolution medium containing phosphate buffer pH 6.8 with 1.0% sodium lauryl sulfate and rotation speed of 100 rpm. The same was obtained for lumefantrine, except the dissolution medium, which was pH 1.2 with 1.0% polysorbate 80. After obtaining the curve of in vitro dissolved fraction versus in vivo absorbed fraction, the calculated coefficient of determination (R squared) was close to 1.00 for both drugs, indicating a level A correlation. Therefore, a novel method for assessing dissolution of arthemeter and lumefantrine tablets was established and validated. (C) 2018 Elsevier B.V. All rights reserved.
机译:疟疾是全世界最突出的寄生虫感染。基于青蒿素的组合疗法(ACT)已提出作为疟疾的有希望的治疗,并且蒿甲醚+ Lumefantrine(20 +120mg)是流行区域推荐的关联。尽管使用广泛使用,但仍然有关于蒿甲醚和Lumefantrine溶解的稀缺信息,反映了在没有药典和国际纲要的特定方法的情况下反映。因为它们的低溶解度,蒿甲醚和Lumefantrine都是体外相关(IVIVC)研究的候选物。使用摇瓶方法和溶出曲线的两种药物对两种药物进行了先前的平衡溶解度研究。用一系列参数进行实验,例如培养基组成,pH和表面活性剂。在先前的药代动力学研究中获得的体内数据用于基于IVIVC选择溶出试验的最佳条件。对于药物定量,优化并验证了高效液相色谱的选择性方法。对于这种剂型,用于伪醚的最佳溶解条件是:桨,含有磷酸盐缓冲液pH 6.8的900ml溶解介质,具有1.0%的十二烷基硫酸钠和100rpm的转速。对于Lumefantrine的Lumefantrine获得了相同的,除了具有1.0%聚山梨醇酯80的pH 1.2的溶解介质。在获得体外溶解级分的曲线与体内吸收级分中,计算的测定系数(R平方)接近1.00对于两种药物,表明水平是相关性。因此,建立并验证了评估菌株和Lumefantrine片剂溶解的新方法。 (c)2018年elestvier b.v.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号